Secondary infertility due to retained fetal bones – a diagnostic dilemma

Puri, Manju; Jain, Shailesh; Bk, Goyal

doi:10.1034/j.1600-0412.2000.079002148.x

Cited by 6 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retained fetal bones should be considered in all patients with infertility, dysfunctional uterine bleeding, dysmenorrhea or other symptoms dating from a pregnancy or pregnancy termination [36,37,38,39,40]. The need to perform transvaginal sonography in all women who present with secondary infertility who had a previous pregnancy that progressed beyond 11 weeks gestation and then ended in spontaneous or therapeutic abortion is mandatory [36].…”

Section: Discussionmentioning

confidence: 99%

Hysteroscopic removal of intrauterine retained fetal bones

et al. 2004

View full text Add to dashboard Cite

Fetus papyraceus is a well-recognized complication of missed abortion or intrauterine fetal death. However, prolonged intrauterine retention of parts of the fetal skeleton is not adequately reported in the literature. Prolonged retention of intrauterine bone is a recognized cause of secondary infertility. Literature regarding endometrial ossification contains more than 80 cases, with 80% occurring after pregnancy. Common symptoms include menorrhagia, menometrorraghia, pelvic pain and infertility. Several theories have been proposed to explain osseous tissue within the uterine cavity. The most widely accepted is that ossification represents retained fetal bones following spontaneous, missed, incomplete or therapeutic abortion, suggesting that the fetus achieved at least 12 weeks gestation in order for endochondral ossification to occur. In contemporary gynecology, transvaginal sonographic diagnosis of retained fetal bones is made and the bones removed with the help of a resectoscope. Hysteroscopy is invaluable in achieving a cure for these patients without resorting to more aggressive surgery. Gonadotropin-releasing hormone analogues (GnRHa) have many new uses in gynecology. Several clinical studies have demonstrated a mean decrease in uterine volume after about 3-6 months of therapy. These patients might be candidates for GnRHa therapy so that a smaller corpus with an atrophic endometrium might aid in hysteroscopic retrieval of the retained bony fragments.

show abstract